期刊
APPLIED RADIATION AND ISOTOPES
卷 55, 期 4, 页码 463-470出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0969-8043(01)00048-3
关键词
radioimmunotherapy; monoclonal antibody; generator; alpha emitting radionuclide; Bi-213; anion exchange purification
类别
资金
- NCI NIH HHS [P01CA33049, R01CA55349] Funding Source: Medline
Alpha emitting radionuclides are of considerable interest for targeted radioimmunotherapy. Generator supplied Bi-213 emitting 8.5 Mev alpha particles with a 45.6 min half-life has been conjugated to a monoclonal antibody (HuM 195-CHX-A-DTPA) for targeted therapy of leukemia in a clinical trial. The clinical dose preparation of pharmaceutical formulation by a pair of skilled radiochemists Look 25 min, which corresponds, to an overall decay loss of 30% of the initial Bi-213 activity eluted from the generator. In order to allow more widespread and practical clinical use of targeted Bi-213 alpha particle therapy, we developed a new procedure that is simpler, more rapid and adaptable to a hospital pharmacy. The new 10 min process includes a tandem elution and labeling, and an anion exchange column purification method that can be reproducibly used. (C) 2001 Elsevier Science Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据